CVS Settles $37.8 Million Lawsuit Over Faulty Insulin Refills

CVS Health has agreed to pay $37.76 million to settle allegations of improper billing for insulin pens dispensed to patients in federal healthcare programs between 2010 and 2020. The company allegedly received reimbursement for refills that were unnecessary, premature, or inaccurately reported, and understated the amount of insulin dispensed. CVS has admitted to certain conduct described in the complaint, including receiving government payments for refills that should not have been reimbursed.